Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines

International Journal of Cancer

Volumn 81, Issue 4, 1999, Pages 620-628

  Burger, Herman ^a   Nooter, Kees ^a   Boersma, Antonius W M ^a   Van Wingerden, Kyra E ^a   Looijenga, Leendert H J ^b   Jochemsen, Aart G ^c   Stoter, Gerrit ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FAS ANTIGEN; MUTANT PROTEIN; PROTEIN P53;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; GAMMA RADIATION; GERM CELL TUMOR; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TESTIS CANCER;

ANTIGENS, CD95; APOPTOSIS; CISPLATIN; DOXORUBICIN; GAMMA RAYS; GENES, P53; GERMINOMA; HUMANS; MALE; SIGNAL TRANSDUCTION; TESTICULAR NEOPLASMS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032963715     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.0.CO;2-S     Document Type: Article

References (32)

1. ANDREWS, P.W. and 15 OTHERS, Comparative analysis of cell-surface antigens expressed by cell lines derived from human germ-cell tumours. Int. J. Cancer, 66, 806-816 (1996).
2. BOERSMA, A.W.M., NOOTER, K., BURGER, H., KORTLAND, C.J. and STOTER, G., Bax upregulation is an early event in cisplatin-induced apoptosis in human testicular germ cell tumour cell line NT2, as quantitated by flow cytometry. Cytometry, 27, 275-282 (1997).
3. BURGER, H., NOOTER, K., BOERSMA, A.W.M., KORTLAND, C.J. and STOTER, G., Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int. J. Cancer, 73, 592-599 (1997).
4. BURGER, H., NOOTER, K., BOERSMA, A.W.M., KORTLAND, C.J. and STOTER, G., Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Brit. J. Cancer, 77, 1562-1567 (1998a).
5. BURGER, H., NOOTER, K., BOERSMA, A.W.M., KORTLAND, C.J., VAN DEN BERG, A.P. and STOTER, G., Expression of p53, p21/WAF/CIP, Bcl-2, Bax, Bcl-X, and Bak in radiation-induced apoptosis in testicular germ cell tumour cell lines. Int. J. Radiat. Oncol. Biol. Phys., 41, 415-424 (1998b).
6. CRESTA, C.M., MASTERS, J.R.W., and HICKMAN, J.A., Hypersensitivity of human testicular tumours to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res., 56, 1834-1841 (1996).
7. EID, H., VAN DER LOOIJ, M., INSTITORIS, E., CECZI, L., BODROGI, I., OLAH, E. and BAK, M., Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res., 17, 2663-2670 (1997).
8. EINHORN, L.H., Treatment of testicular cancer: a new and improved model. J. clin. Oncol., 8, 1777-1781 (1990).
9. FAN, S., SMITH, M.L., RIVET, D.J., DUBA, D., ZHAN, Q., KOHN, K.W., FORNACE, A.J. and O'CoNNOR, P.M., Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55, 1649-1654 (1995).
10. FISHER, D.E., Apoptosis in cancer therapy: crossing the threshold. Cell, 78, 539-542 (1994).
11. FRIESEN, C. HERR, I., KRAMMER, P.H. and DEBATIN, K-M., Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med., 2, 574-577 (1996).
12. HAIMOVITZ-FRIEDMAN, A., KAN, C.C., EHLEITER, D., PERSAUD, R.S., MCLOUGHLIN, M., FUKS, Z. and KOLESNICK, R.N., Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. exp. Med., 180, 525-535 (1994).
13. HARRIS, C.C., Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. nat. Cancer Inst., 88, 1442-1452 (1996).
14. HAWKINS, D.S., DEMERS, G.W. and GALLOWAY, D.A., Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892-898 (1996).
15. HEIDENREICH, A., SCHENKMAN, N.S., SESTERHENN, I.A., MOSTOFI, K.F., MOUL, J.W., SRIVASTAVA, S. and ENGELMANN, D.H., Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular-germ-cell tumours. APMIS, 106, 90-100 (1998).
16. HEIMDAHL, K., LOTHE, R.A., LYSTAD, S., HOLM, R., FOSSA, S. and BORRESSEN, A.L., No germline TP53 mutations detected in familial and bilateral testicular cancer. Genes, Chromosomes Cancer, 6, 92-97 (1993).
17. HOULDSWORTH, J., XIAO, H., MURTY, V.V.V.S., CHEN, W., RAY, B., REUTER, V.E., BOSL, G.J. and CHAGANTI, R.S.K., Human male germ cell tumour resistance to cisplatin is linked to TP53 gene mutation. Oncogene, 16, 2345-2349 (1998).
18. JARVIS, W.D., GRANT, S. and KOLESNICK, R.N., Ceramide and the induction of apoptosis. Clin. Cancer Res., 2, 1-6 (1996).
19. JOST, C.A., MARIN, M.C. and KAELIN JR., W.G., p73 is a human p53-related protein that can induce apoptosis. Nature (Lond.), 389, 191-194 (1997).
20. KUCZYK, M.A., SERTH, J., BOKEMEYER, C., JONASSEN, J., MACHTENS, S., WERNER, M. and JONAS, U., Alterations of the p53 tumour suppressor gene in carcinoma in situ of the testis. Cancer, 78, 1958-1966 (1996).
21. LEWIS, D.J., SESTERHENN, I.A., MCCARTHY, W.F. and MOUL, J.W., Immunohistochemical expression of p53 tumour suppressor gene protein in adult germ-cell testis tumours: clinical correlation in stage I disease. J. Urol., 152, 418-423 (1994).
22. LOWE, S.W., RULEY, H.E., JACKS, T. and HOUSMAN, D.E., p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967 (1993).
23. LUTZKER, S.G., p53 tumour-suppressor gene and germ-cell neoplasia. APMIS, 106, 85-89 (1998).
24. MARTIN, S.J. and GREEN, D.R., Protease activation during apoptosis: death by a thousand cuts?. Cell, 82, 349-352 (1995).
25. NAGATA, S., Apoptosis by death factor. Cell. 88, 355-365 (1997).
26. OBEID, L.M., LINARDIC, C.M., KAROLAK, L.A. and HANNUN, Y.A., Programmed cell death induced by ceramide. Science, 259, 1769-1771 (1993).
27. OSADA, M., OHBA, M., KAWAHARA, C., ISHIOKA, C., KNAMARU, R., KATOH, I., IKAWA, Y., NIMURA, Y., NAKAGAWARA, A., OBINATA, M. and IKAWA, S., Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med., 7, 839-843 (1998).
28. SARK, M.W.J., TIMMER-BOSSCHA, H., MEIJER, C., UGES, D.R.A., SLUITER, W.J., PETERS, W.H.M., MULDER, N.H. and DE VRIES, E.G.E., Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Brit. J. Cancer, 71, 684-690 (1995).
29. THOMPSON, C.B., Apoplosis in the pathogenesis and treatment of disease. Science, 267, 1456-1462 (1995).
30. UNGER, C., BUCHMANN, A., BUENEMANN, C.L., KRESS, S. and SCHWARZ, M., Wild-type function of the p53 tumour-suppressor protein is not required for apoptosis of mouse hepatoma cells. Cell Death Differ., 5, 87-95 (1998).
31. VERHEIJ, M., and 12 OTHERS, Requirement for ceramide-initiated SAPK/ JNK signalling in stress-induced apoptosis. Nature (Lond.), 380, 75-79 (1996).
32. ZAMBLE, D.B., JACKS, T. and LIPPARD, S.J., p53-dependent and -independent responses to cisplatin in mouse testicular-teratocarcinoma cells. Proc. nat. Acad. Sci. (Wash.), 95, 6163-6168 (1998).